Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline

Journals

remove_circle_outline

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = cardiac rhythm management devices (CRMDs)

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
2 pages, 98 KB  
Commentary
Perspectives on the Longevity of Cardiac Rhythm Management Devices
by John Fanourgiakis
Cardiovasc. Med. 2024, 27(4), 127; https://doi.org/10.4414/cvm.2024.1443408577 - 14 Aug 2024
Viewed by 368
Abstract
Cardiac arrhythmias are a major cause of morbidity and mortality. Cardiac rhythm management devices (CRMDs) are used to diagnose and treat heart rhythm abnormalities. Many prospective randomized trials over the past decade have established the efficacy of CRMD therapy in reducing all-cause mortality [...] Read more.
Cardiac arrhythmias are a major cause of morbidity and mortality. Cardiac rhythm management devices (CRMDs) are used to diagnose and treat heart rhythm abnormalities. Many prospective randomized trials over the past decade have established the efficacy of CRMD therapy in reducing all-cause mortality and improving the quality of life. The manufacturer of every device provides its longevity in its technical characteristics, which are, as studies show, shorter in practice. Patients are concerned about the replacement procedure due to the risk of the procedure and other socioeconomic reasons. The longer the longevity of the devices, the better for the patients, the payers, the doctors and the health care systems. Given the recently redefined term of health technology assessment on a European level, a new regulatory framework has been proposed. Its intention is that, across different healthcare systems, the upfront costs and the reimbursement costs of these devices should be proportional to their longevity. Full article
Back to TopTop